Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 104

Results For "CARE"

4006 News Found

GSK signs $745 million licensing agreement with Empirico for novel respiratory siRNA therapy
News | October 31, 2025

GSK signs $745 million licensing agreement with Empirico for novel respiratory siRNA therapy

The deal reinforces GSK’s leadership in respiratory care and builds upon the company’s expanding COPD portfolio


BMS’ Cobenfy sees steady start, eyes stronger growth ahead
News | October 31, 2025

BMS’ Cobenfy sees steady start, eyes stronger growth ahead

Cobenfy generated $43 million in third-quarter sales, up from $35 million in the second quarter


AbbVie’s RINVOQ shows promise in Vitiligo Phase 3 trials
News | October 31, 2025

AbbVie’s RINVOQ shows promise in Vitiligo Phase 3 trials

Vitiligo, affecting over 90 per cent of patients in its non-segmental form, is characterized by symmetrical white patches on both sides of the body


FUJIFILM India unveils FW500, advancing biochemistry innovation in diagnostics
News | October 31, 2025

FUJIFILM India unveils FW500, advancing biochemistry innovation in diagnostics

The FW500 is designed to meet the evolving needs of mid-sized diagnostic laboratories


EU approves Alexion’s Koselugo to treat adults with neurofibromatosis type 1 tumours
Clinical Trials | October 31, 2025

EU approves Alexion’s Koselugo to treat adults with neurofibromatosis type 1 tumours

Approval based on pivotal KOMET Phase III trial demonstrating significant tumour reduction in adults with NF1


Shaquille O’Neal and Lilly join forces to tackle sleep apnea awareness
News | October 31, 2025

Shaquille O’Neal and Lilly join forces to tackle sleep apnea awareness

Basketball legend, entrepreneur, and entertainer Shaquille O’Neal partners with Lilly to encourage Americans to recognize the signs of obstructive sleep apnea and talk to their


Alexion highlights breakthrough C5 inhibition advances in gMG at 2025 AANEM and MGFA scientific sessions
Clinical Trials | October 31, 2025

Alexion highlights breakthrough C5 inhibition advances in gMG at 2025 AANEM and MGFA scientific sessions

New Phase III data on gefurulimab highlight potential as a self-administered treatment option; real-world evidence reinforces clinical benefits of Ultomiris and Soliris